TORONTO, May 13, 2015 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") today announced that all of the nominee directors listed in the Company's management information circular dated April 8, 2015, were elected as directors of the Company. The vote was conducted at the Company's annual and special meeting of shareholders held on May 12, 2015. The results of the vote are set out below:
|
Nominee |
Votes For |
Votes Withheld |
Percentage of Votes For |
Percentage of Votes Withheld |
| James Howard-Tripp | 17,991,601 | 7,300 | 99.96 | 0.04 |
| Rory Riggs | 17,995,901 | 3,000 | 99.98 | 0.02 |
| Heiner Dreismann | 17,998,901 | 6,000 | 99.97 | 0.03 |
| Harry Glorikian | 17,992,901 | 3,000 | 99.98 | 0.02 |
| Garth MacRae | 17,994,601 | 4,300 | 99.98 | 0.02 |
| Leslie Auld | 17,992,901 | 6,000 | 97.97 | 0.03 |
| Floyd C. Dent III | 17,995,901 | 3,000 | 99.98 | 0.02 |
About GeneNews
GeneNews is focused on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a primary focus on cancer-related indications. The Company's lead product, ColonSentry®, is the world's first blood test to assess an individual's current risk for colorectal cancer. In 2013, GeneNews created a U.S. joint venture, Innovative Diagnostic Laboratory, LLP ("IDL"), that it is committed to help become a leader in molecular diagnostics and personalized medicine, serving as a strong commercialization outlet for advanced cancer tests. Taking a multi-view approach to the diagnosis and treatment of cancer, IDL is working to assemble, through a combination of internal pipeline development, third-party licenses and potential acquisitions, a robust menu of novel, proprietary tests to be offered by it throughout the United States. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com and www.MyInnovativeLab.com, respectively.